ATAI Life Sciences NV (9VC) - Net Assets
Based on the latest financial reports, ATAI Life Sciences NV (9VC) has net assets worth €159.91 Million EUR (≈ $186.95 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€239.82 Million ≈ $280.37 Million USD) and total liabilities (€79.91 Million ≈ $93.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 9VC tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €159.91 Million |
| % of Total Assets | 66.68% |
| Annual Growth Rate | 14.33% |
| 5-Year Change | 22.21% |
| 10-Year Change | N/A |
| Growth Volatility | 130.6 |
ATAI Life Sciences NV - Net Assets Trend (2019–2024)
This chart illustrates how ATAI Life Sciences NV's net assets have evolved over time, based on quarterly financial data. See 9VC days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ATAI Life Sciences NV (2019–2024)
The table below shows the annual net assets of ATAI Life Sciences NV from 2019 to 2024. For live valuation and market cap data, see 9VC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €116.55 Million ≈ $136.26 Million |
-52.29% |
| 2023-12-31 | €244.32 Million ≈ $285.63 Million |
-8.07% |
| 2022-12-31 | €265.77 Million ≈ $310.71 Million |
-31.14% |
| 2021-12-31 | €385.96 Million ≈ $451.23 Million |
+304.70% |
| 2020-12-31 | €95.37 Million ≈ $111.50 Million |
+59.91% |
| 2019-12-31 | €59.64 Million ≈ $69.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ATAI Life Sciences NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68005500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €816.50 Million | 702.09% |
| Total Equity | €116.30 Million | 100.00% |
ATAI Life Sciences NV Competitors by Market Cap
The table below lists competitors of ATAI Life Sciences NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Radiant Opto-Electronics Corp
TW:6176
|
$1.27 Billion |
|
Advtech
JSE:ADH
|
$1.27 Billion |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MC:LDA
|
$1.27 Billion |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
$1.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
$1.27 Billion |
|
Is Yatirim Menkul Degerler AS
IS:ISMEN
|
$1.27 Billion |
|
Cosmax Inc
KO:192820
|
$1.27 Billion |
|
SkiStar AB (publ)
ST:SKIS-B
|
$1.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ATAI Life Sciences NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 242,962,000 to 116,297,000, a change of -126,665,000 (-52.1%).
- Net loss of 149,269,000 reduced equity.
- Other factors increased equity by 22,604,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-149.27 Million | -128.35% |
| Other Changes | €22.60 Million | +19.44% |
| Total Change | €- | -52.13% |
Book Value vs Market Value Analysis
This analysis compares ATAI Life Sciences NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.86x to 4.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.39 | €3.43 | x |
| 2020-12-31 | €0.60 | €3.43 | x |
| 2021-12-31 | €2.35 | €3.43 | x |
| 2022-12-31 | €1.57 | €3.43 | x |
| 2023-12-31 | €1.46 | €3.43 | x |
| 2024-12-31 | €0.69 | €3.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ATAI Life Sciences NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -128.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48463.96%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-128.35%) is below the historical average (-76.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -24.06% | 0.00% | 0.00x | 1.06x | €-20.01 Million |
| 2020 | -187.01% | 0.00% | 0.00x | 1.23x | €-178.93 Million |
| 2021 | -44.52% | -823.56% | 0.05x | 1.10x | €-205.50 Million |
| 2022 | -58.44% | -65401.29% | 0.00x | 1.17x | €-178.46 Million |
| 2023 | -16.56% | -12810.19% | 0.00x | 1.21x | €-64.52 Million |
| 2024 | -128.35% | -48463.96% | 0.00x | 1.37x | €-160.90 Million |
Industry Comparison
This section compares ATAI Life Sciences NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,435,678,106
- Average return on equity (ROE) among peers: -30.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ATAI Life Sciences NV (9VC) | €159.91 Million | -24.06% | 0.50x | $1.27 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $179.82 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $20.05 Billion |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more